Janelle C Waite - JoVE Visualize

Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Policies

Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Policies

Filters

Janelle C Waite

Showing results (11-20 of 13) with videos related to

Pageof 2

Sort By:

You have reached the last page of results.This site can display upto 13 results.

Nature Communications|April 30, 2015

Id1 suppresses anti-tumour immune responses and promotes tumour progression by impairing myeloid cell maturationMarianna Papaspyridonos, Irina Matei, Yujie Huang, et al.

Science Translational Medicine|January 10, 2020

A class of costimulatory CD28-bispecific antibodies that enhance the antitumor activity of CD3-bispecific antibodiesDimitris Skokos, Janelle C Waite, Lauric Haber, et al.

Science Translational Medicine|June 26, 2020

Tumor-targeted CD28 bispecific antibodies enhance the antitumor efficacy of PD-1 immunotherapyJanelle C Waite, Bei Wang, Lauric Haber, et al.

Pageof 2

Search research articles

Showing results (11-20 of 13) with videos related to

Sort By:

Pageof 2

You have reached the last page of results.This site can display upto 13 results.

Nature Communications|April 30, 2015

Id1 suppresses anti-tumour immune responses and promotes tumour progression by impairing myeloid cell maturationMarianna Papaspyridonos, Irina Matei, Yujie Huang, et al.

Science Translational Medicine|January 10, 2020

A class of costimulatory CD28-bispecific antibodies that enhance the antitumor activity of CD3-bispecific antibodiesDimitris Skokos, Janelle C Waite, Lauric Haber, et al.

Science Translational Medicine|June 26, 2020

Tumor-targeted CD28 bispecific antibodies enhance the antitumor efficacy of PD-1 immunotherapyJanelle C Waite, Bei Wang, Lauric Haber, et al.

Pageof 2